Patients who were age ≥18, had ≥1 claim with a T2DM diagnosis, no claims with a gestational diabetes diagnosis, and had continuous enrollment six months pre-and post-index were included.
RESULTS:
Patients who initiated dulaglutide were 53% female, mostly aged 40-64 (82%), and had a mean Deyo Charlson comorbidity index of 1.8, similar to all other GLP-1 RAs. The most common comorbidities across all GLP-1 RAs were hypertension (66-69%) and hyperlipidemia (59-67%). During the pre-index period, the dulaglutide initiators had significantly higher proportion of patients with endocrinologist visits (39%) than each of the other GLP-1 RA (17-27%). Prior use of SGLT2 inhibitors (28%) and insulin (43%) during the pre-index period were significantly higher for dulaglutide initiators than each of the other GLP-1 RAs except for albiglutide. Approximately onethird of dulaglutide initiators (32%) were previously on another GLP-1 RA, primarily liraglutide (16%) and exenatide QW (13%). More than half of dulaglutide patients were initiated on dulaglutide 0.75 mg (54%).
CONCLUSIONS:
Baseline demographics and patient characteristics were overall similar between dulaglutide and other GLP-1 RAs with the exception of higher endocrinologist visits. Dulaglutide had higher prior use of insulin and SGLT2 inhibitors compared to exenatide BID, exenatide QW, and liraglutide. • Naïve to index GLP-1 RA in the previous 6 months
• ≥18 years of age or older at the index date
• At least one claim with a T2DM diagnosis (ICD-9-CM 250.x0, 250.x2) during the pre-index period
• 6 months continuous eligibility in the pre-and post-index periods
• No evidence of gestational diabetes (ICD-9-CM 648.8x) diagnoses during the pre-index period (5) 272 (5) 72 (5) 503 (6) 82 (6) Depression 215 (9) 435 (9) 144 (11) 819 (9) 113 (8 
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